



US009045462B2

(12) **United States Patent**
Evans et al.

(10) **Patent No.:** **US 9,045,462 B2**
(45) **Date of Patent:** ***Jun. 2, 2015**

(54) **SYNTHESIS OF AN ANTIVIRAL COMPOUND**

(71) Applicant: **Gilead Sciences, Inc.**, Foster City, CA (US)

(72) Inventors: **Jared Wayne Evans**, Belmont, CA (US); **Shinji Fujimori**, San Francisco, CA (US); **Grace M. Huynh**, San Francisco, CA (US); **Qi Liu**, Union City, CA (US); **Martin Gerald Teresk**, San Jose, CA (US)

(73) Assignee: **Gilead Sciences, Inc.**, Foster City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/271,216**

(22) Filed: **May 6, 2014**

(65) **Prior Publication Data**

US 2014/0275570 A1 Sep. 18, 2014

Related U.S. Application Data

(63) Continuation of application No. 13/801,039, filed on Mar. 13, 2013, now Pat. No. 8,759,544.

(60) Provisional application No. 61/684,543, filed on Aug. 17, 2012.

(51) **Int. Cl.**

C07D 409/12 (2006.01)

C07D 307/20 (2006.01)

(52) **U.S. Cl.**

CPC **C07D 409/12** (2013.01); **C07D 307/20** (2013.01)

(58) **Field of Classification Search**

CPC C07D 409/12; C07D 307/20

USPC 549/60

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,861,421	A	1/1999	Christensen, IV et al.
6,881,741	B2	4/2005	Chan Chun Kong et al.
6,887,877	B2	5/2005	Chan Chun Kong et al.
7,402,608	B2	7/2008	Chan Chun Kong et al.
7,521,473	B2	4/2009	Lee et al.
7,569,600	B2	8/2009	Denis et al.
2002/0002199	A1	1/2002	Jeppesen et al.
2003/0229053	A1	12/2003	Chan Chun Kong et al.
2004/0116509	A1	6/2004	Chan Chun Kong et al.
2005/0119332	A1	6/2005	Jeppesen et al.
2006/0142347	A1	6/2006	Chan Chun Kong et al.
2006/0276533	A1	12/2006	Denis et al.
2007/0099929	A1	5/2007	Thede et al.
2008/0299080	A1	12/2008	Chan Chun Kong et al.
2009/0274655	A1	11/2009	Grimes et al.
2011/0020278	A1	1/2011	Canales et al.

2011/0178058	A1	7/2011	Canales et al.
2011/0178129	A1	7/2011	Canales et al.
2013/0052161	A1	2/2013	Watkins
2014/0051749	A1	2/2014	Hashash et al.
2014/0051866	A1	2/2014	Watkins et al.

FOREIGN PATENT DOCUMENTS

WO	02/100846	A1	12/2002
WO	02/100851	A2	12/2002
WO	2004/052885		6/2004
WO	2005/095386	A1	10/2005
WO	2006/072347	A2	7/2006
WO	2006/072348		7/2006
WO	2007/093365	A2	8/2007
WO	2008/058393	A1	5/2008
WO	2010/065668		6/2010
WO	2011/011303		1/2011
WO	2011/031669		3/2011
WO	2011/068715		6/2011
WO	2011/088345	A1	7/2011
WO	2012/006055		1/2012
WO	2012/087596	A1	6/2012

OTHER PUBLICATIONS

Notice of Allowance for U.S. Appl. No. 13/006,761, mailed Oct. 3, 2012.

Notice of Allowance for U.S. Appl. No. 13/392,467, mailed Sep. 21, 2012.

Office Action for U.S. Appl. No. 12/838,684, mailed Aug. 2, 2012.

Boyer, N, et al. (2000) "Pathogenesis, diagnosis and management of hepatitis C," *Journal of Hepatology* 32 (suppl 1):98-112.

Calisher, C. et al. (1989) "Antigenic Relationships between *Flaviviruses* as Determined by Cross-neutralization Tests with Polyclonal Antisera," *J. gen. Virol.* 70:37-43.

Di Bisceglie, A. et al. (1999) "Some 1.8 percent of the U.S. adult population are infected with the hepatitis C virus, most without knowing it" *Scientific American* October pp. 80-85.


(Continued)

Primary Examiner — Noble Jarrell

Assistant Examiner — John Mauro

(57) **ABSTRACT**

The present disclosure provides processes for the preparation of a compound of Formula I:



which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula.

19 Claims, No Drawings